Comment from PCCA
AnonymousSupportTrade association
Summary: The Pharmaceutical Compounding Association of America (PCCA) is providing information to support the nomination of melatonin to the 503A Bulk Drug Substances list. They argue that melatonin is a valuable and effective tool for managing sleep dysfunction in patients with autism spectrum disorders, citing clinical data and international guidelines.
This comment is in response to FDA's request for clarification for the nomination of melatonin to the 503A Bulk Drug Substances List.